Matches in SemOpenAlex for { <https://semopenalex.org/work/W2093281417> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2093281417 endingPage "207" @default.
- W2093281417 startingPage "202" @default.
- W2093281417 abstract "Background and Objectives The combination of 5-fluorouracil and radiotherapy is thought to be the most effective treatment for locally unresectable pancreatic carcinoma. The outcomes, however, are far from acceptable from the viewpoint of long-term survival. We assessed the survival benefits of oral adjuvant chemotherapy with doxifluridine (5′-DFUR) following radiotherapy for patients with the disease. Methods Thirty-five consecutive patients who underwent bypass surgery and radiotherapy for localized advanced unresectable adenocarcinoma of the pancreas head were retrospectively reviewed in regard to disease progression and survival. Ten of the 35 patients underwent adjuvant chemotherapy with 5′-DFUR after radiotherapy in an outpatient setting. Results The 1-year survival for patients treated with radiotherapy alone was 29%. The 1-, 2-, and 3-year survivals for patients treated with the adjuvant chemotherapy after radiotherapy were 50, 40, and 30%, respectively (P = 0.0069, log-rank test). The elevation of tumor markers was delayed (P = 0.0346) and local control rate was improved (P = 0.0475) in patients with chemotherapy. Multivariate analysis demonstrated that the adjuvant chemotherapy with 5′-DFUR was a significant independent prognostic factor as well as tumor size. Conclusions The adjuvant chemotherapy with 5′-DFUR following radiotherapy led to a significant prolongation of the survival for patients with unresectable localized pancreatic cancer. J. Surg. Oncol. 2001;78:202–207. © 2001 Wiley-Liss, Inc." @default.
- W2093281417 created "2016-06-24" @default.
- W2093281417 creator A5043208342 @default.
- W2093281417 creator A5066700160 @default.
- W2093281417 creator A5076911008 @default.
- W2093281417 creator A5082992678 @default.
- W2093281417 creator A5084684329 @default.
- W2093281417 creator A5089230325 @default.
- W2093281417 date "2001-01-01" @default.
- W2093281417 modified "2023-09-27" @default.
- W2093281417 title "Survival benefits of adjuvant chemotherapy with oral doxifluridine (5?-DFUR) following radiotherapy in patients with unresectable pancreatic cancer" @default.
- W2093281417 cites W1926559864 @default.
- W2093281417 cites W1968400301 @default.
- W2093281417 cites W1972373303 @default.
- W2093281417 cites W1983513991 @default.
- W2093281417 cites W1985561102 @default.
- W2093281417 cites W1989407605 @default.
- W2093281417 cites W1999340738 @default.
- W2093281417 cites W2037702322 @default.
- W2093281417 cites W2040486088 @default.
- W2093281417 cites W2055561367 @default.
- W2093281417 cites W2080080319 @default.
- W2093281417 cites W2240373795 @default.
- W2093281417 cites W2335208141 @default.
- W2093281417 cites W2437204367 @default.
- W2093281417 cites W4253922044 @default.
- W2093281417 doi "https://doi.org/10.1002/jso.1151" @default.
- W2093281417 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11745808" @default.
- W2093281417 hasPublicationYear "2001" @default.
- W2093281417 type Work @default.
- W2093281417 sameAs 2093281417 @default.
- W2093281417 citedByCount "6" @default.
- W2093281417 crossrefType "journal-article" @default.
- W2093281417 hasAuthorship W2093281417A5043208342 @default.
- W2093281417 hasAuthorship W2093281417A5066700160 @default.
- W2093281417 hasAuthorship W2093281417A5076911008 @default.
- W2093281417 hasAuthorship W2093281417A5082992678 @default.
- W2093281417 hasAuthorship W2093281417A5084684329 @default.
- W2093281417 hasAuthorship W2093281417A5089230325 @default.
- W2093281417 hasConcept C121608353 @default.
- W2093281417 hasConcept C126322002 @default.
- W2093281417 hasConcept C141071460 @default.
- W2093281417 hasConcept C143998085 @default.
- W2093281417 hasConcept C2776694085 @default.
- W2093281417 hasConcept C2777546739 @default.
- W2093281417 hasConcept C2777863537 @default.
- W2093281417 hasConcept C2780210213 @default.
- W2093281417 hasConcept C2781182431 @default.
- W2093281417 hasConcept C509974204 @default.
- W2093281417 hasConcept C71924100 @default.
- W2093281417 hasConceptScore W2093281417C121608353 @default.
- W2093281417 hasConceptScore W2093281417C126322002 @default.
- W2093281417 hasConceptScore W2093281417C141071460 @default.
- W2093281417 hasConceptScore W2093281417C143998085 @default.
- W2093281417 hasConceptScore W2093281417C2776694085 @default.
- W2093281417 hasConceptScore W2093281417C2777546739 @default.
- W2093281417 hasConceptScore W2093281417C2777863537 @default.
- W2093281417 hasConceptScore W2093281417C2780210213 @default.
- W2093281417 hasConceptScore W2093281417C2781182431 @default.
- W2093281417 hasConceptScore W2093281417C509974204 @default.
- W2093281417 hasConceptScore W2093281417C71924100 @default.
- W2093281417 hasIssue "3" @default.
- W2093281417 hasLocation W20932814171 @default.
- W2093281417 hasLocation W20932814172 @default.
- W2093281417 hasOpenAccess W2093281417 @default.
- W2093281417 hasPrimaryLocation W20932814171 @default.
- W2093281417 hasRelatedWork W1505417176 @default.
- W2093281417 hasRelatedWork W200989379 @default.
- W2093281417 hasRelatedWork W2355437398 @default.
- W2093281417 hasRelatedWork W2364854402 @default.
- W2093281417 hasRelatedWork W2373977476 @default.
- W2093281417 hasRelatedWork W2376347278 @default.
- W2093281417 hasRelatedWork W2407189953 @default.
- W2093281417 hasRelatedWork W2469468620 @default.
- W2093281417 hasRelatedWork W271211968 @default.
- W2093281417 hasRelatedWork W4235547508 @default.
- W2093281417 hasVolume "78" @default.
- W2093281417 isParatext "false" @default.
- W2093281417 isRetracted "false" @default.
- W2093281417 magId "2093281417" @default.
- W2093281417 workType "article" @default.